Patient with CADASIL – a diagnostic challenge
 
More details
Hide details
1
Studenckie Koło Naukowe przy Katedrze i Zakładzie Farmakologii, Wydział Nauk Medycznych w Zabrzu, Śląski Uniwersytet Medyczny w Katowicach / Students’ Scientific Club, Department of Pharmacology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland
 
2
Poradnia Genetyczna i Diagnostyki Prenatalnej, Samodzielny Publiczny Szpital Kliniczny Nr 1 im. prof. Stanisława Szyszko Śląskiego Uniwersytetu Medycznego w Katowicach / The Independent Public Clinical Hospital No.1 Prof. Stanislaw Szyszko of the Medical University of Silesia, Katowice, Poland
 
 
Corresponding author
Julia Węgrzynek   

Studenckie Koło Naukowe przy Katedrze i Zakładzie Farmakologii, Wydział Nauk Medycznych w Zabrzu, Śląski Uniwersytet Medyczny w Katowicach, ul. Jordana 38, 41-808 Zabrze
 
 
Ann. Acad. Med. Siles. 2023;77:151-157
 
KEYWORDS
TOPICS
ABSTRACT
INTRODUCTION: Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is a genetically determined and hereditary cerebral small vessel disease caused by mutations in the NOTCH3 gene. The onset is in the 3rd and 4th decade of life and is preceded by leukodegenerative changes, which are best visualized by magnetic resonance imaging (MRI). The prevalence of CADASIL is estimated at 2 to 5 people in 100,000. The clinical picture is heterogenous. The main clinical features include recurrent subcortical ischemic events, mood disturbances, progressive cognitive impairment and migraines with aura. Despite the growing recognition of CADASIL, this disease is still a diagnostic challenge. CASE REPORT: A 60-year-old man was referred to the genetic clinic for suspected CADASIL. The initial clinical symptoms probably occurred at the age of 40 in the form of radiological changes. The MRI performed then revealed periventricular zones of a T2 hyperintense signal. Based on follow-up MRIs, the patient was diagnosed with multiple sclerosis or acute disseminated encephalomyelitis. At the age of 58, following a seizure attack he was admitted to hospital and a performed MRI that revealed periventricular white matter degeneration and lacunes. CADASIL was suspected to be the cause. The diagnosis was confirmed by molecular testing. A pathogenic variant NM_000435: c.268C > T (p.Arg90Cys) was detected. CONCLUSIONS: It is relevant to pay attention to radiological findings and family history in the diagnostic process of a patient presenting symptoms which may suggest CADASIL to differentiate this genetic condition from demyelinating diseases.
 
REFERENCES (17)
1.
Gallardo A., Latapiat V., Rivera A., Fonseca B., Roldan A., Sandoval P. I wsp. NOTCH3 gene mutation in a Chilean cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy family. J. Stroke Cerebrovasc. Dis. 2020; 29(2): 104530, doi: 10.1016/j.jstrokecerebrovasdis.2019.104530.
 
2.
Ferrante E.A., Cudrici C.D., Boehm M. CADASIL: new advances in basic science and clinical perspectives. Curr. Opin. Hematol. 2019; 26(3): 193–198, doi: 10.1097/MOH.0000000000000497.
 
3.
Mizuno T., Mizuta I., Watanabe-Hosomi A., Mukai M., Koizumi T. Clinical and genetic aspects of CADASIL. Front. Aging Neurosci. 2020; 12: 91, doi: 10.3389/fnagi.2020.00091.
 
4.
Joutel A., Vahedi K., Corpechot C., Troesch A., Chabriat H., Vayssière C. i wsp. Strong clustering and stereotyped nature of Notch3 mutations in CADASIL patients. Lancet 1997; 350(9090): 1511–1515, doi: 10.1016/S0140-6736(97)08083-5.
 
5.
Chen X., Deng S., Xu H., Hou D., Hu P., Yang Y. i wsp. Novel and recurring NOTCH3 mutations in two Chinese patients with CADASIL. Neurodegener. Dis. 2019; 19(1): 35–42, doi: 10.1159/000500166.
 
6.
Shahien R., Bianchi S., Bowirrat A. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy in an Israeli family. Neuropsychiatr. Dis. Treat. 2011; 7: 383–390, doi: 10.2147/NDT.S19399.
 
7.
Stojanov D., Vojinovic S., Aracki-Trenkic A., Tasic A., Benedeto-Stojanov D., Ljubisavljevic S. i wsp. Imaging characteristics of cerebral autosomal dominant arteriopathy with subcortical infarcts and leucoencephalopathy (CADASIL). Bosn. J. Basic Med. Sci. 2015; 15(1): 1–8, doi: 10.17305/bjbms.2015.247.
 
8.
Locatelli M., Padovani A., Pezzini A. Pathophysiological mechanisms and potential therapeutic targets in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL). Front. Pharmacol. 2020; 11: 321, doi: 10.3389/fphar.2020.00321.
 
9.
Paraskevas G.P., Stefanou M.I., Constantinides V.C., Bakola E., Chondrogianni M., Giannopoulos S. i wsp. CADASIL in Greece: Mutational spectrum and clinical characteristics based on a systematic review and pooled analysis of published cases. Eur. J. Neurol. 2022; 29(3): 810–819, doi: 10.1111/ene.15180.
 
10.
Stojanov D., Grozdanović D., Petrović S., Benedeto-Stojanov D., Stefanović I., Stojanović N. i wsp. De novo mutation in the NOTCH3 gene causing CADASIL. Bosn. J. Basic Med. Sci. 2014; 14(1): 48–50, doi: 10.17305/bjbms.2014.2297.
 
11.
Sathe S., Nunziato E.C. How often is CADASIL diagnosed as multiple sclerosis? Neurology 2015; 84(Suppl 14): P4.076.
 
12.
Carone D.A. CADASIL and multiple sclerosis: A case report of prolonged misdiagnosis. Appl. Neuropsychol. Adult 2017; 24(3): 294–297, doi: 10.1080/23279095.2016.1214132.
 
13.
Khan A., Abedi V., Li J., Malik M.T., Esch M., Zand R. CADASIL vs. multiple sclerosis: Is it misdiagnosis or concomitant? A case series. Front. Neurol. 2020; 11: 860, doi: 10.3389/fneur.2020.00860.
 
14.
Klineova S., Lublin F.D. Clinical course of multiple sclerosis. Cold Spring Harb. Perspect. Med. 2018; 8(9): a028928, doi: 10.1101/cshperspect.a028928.
 
15.
Pohl D., Alper G., Van Haren K., Kornberg A.J., Lucchinetti C.F., Tenembaum S. et al. Acute disseminated encephalomyelitis. Updates on an inflammatory CNS syndrome. Neurology 2016; 87(9 Suppl 2): S38–45, doi: 10.1212/WNL.0000000000002825.
 
16.
Paraskevas G.P., Constantinides V.C., Kapaki E. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leucoencephalopathy vs. multiple sclerosis. Either one or sometimes both? Neuroimmunol. Neuroinflammation 2018; 5: 49, doi: 10.20517/2347-8659.2018.50.
 
17.
Adamczyk-Sowa M., Kalinowska A., Siger M., Kułakowska A., Rejdak K., Potemkowski A. i wsp. Diagnostyka stwardnienia rozsianego: Rekomendacje Sekcji Stwardnienia Rozsianego i Neuroimmunologii Polskiego Towarzystwa Neurologicznego. Pol. Przegl. Neurol. 2021; 17(4): 149–164, doi: 10.5603/PPN.2021.0028.
 
eISSN:1734-025X
Journals System - logo
Scroll to top